|

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

RECRUITINGPhase 2Sponsored by Alveus Therapeutics, Inc.
Actively Recruiting
PhasePhase 2
SponsorAlveus Therapeutics, Inc.
Started2026-08-10
Est. completion2027-08-24
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations20 sites

Summary

A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Key inclusion criteria

1. Adult male and female participants, aged ≥18 to ≤75
2. BMI ≥23 kg/m2 at screening.
3. Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening.
4. Tolerating incretin-based therapy at the discretion of the investigator
5. WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening.
6. Willing to maintain their current general diet and physical activity regimen throughout the study.

Key exclusion criteria

1. Lifetime history of Type 1 or Type 2 diabetes
2. Prior obesity treatment with surgery or a weight loss device.
3. Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity.
4. Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain.
5. Family or personal history of MTC or MEN 2
6. Presence or history of malignant neoplasms within the past 5 years prior to screening

Conditions3

AdultsOverweight/ObesityWeight Loss

Interventions1

Locations20 sites

University of Alabama - Birmingham
Birmingham, Alabama, 35294
Shruti Sukhanandi205-934-4980sbsukhan@uab.edu
DM Clinical Research
Sun City, Arizona, 85373
Katrina Spencer, MD602-325-1553Katrina.Spencer@dmclinical.com
AMR Clinical
Tempe, Arizona, 85281
Sandy Quintanilla602-910-3343sandy.quintanilla@amr-clinical.com
Profound Research
Oceanside, California, 92058
Christina Spencer760-826-2020Christina.Spencer@profoundresearch.com
DM Clinical Research
Bradenton, Florida, 34209
Principal Investigator407-508-8249jeremy.mcconnell@dmclinical.com

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.